Kentucky licensing board to create exemptions for controlled substance prescriptions

Kentucky's House Bill 389, introduced on March 6, 2025, is making waves in the state legislature by expanding the prescribing powers of licensed optometrists and dentists. This bill aims to address the growing need for accessible pain management options, particularly in the wake of oral surgeries, while also tackling the ongoing opioid crisis.

At the heart of HB 389 is a provision that allows licensed optometrists to prescribe Schedule III, IV, or V controlled substances, a move that has sparked significant debate among healthcare professionals and lawmakers. Proponents argue that this change will enhance patient care by enabling optometrists to manage pain effectively, especially after procedures like cataract surgery. Meanwhile, dentists will be permitted to prescribe a three-day supply of Schedule III controlled substances post-oral surgery, a measure designed to streamline patient recovery.

However, the bill has not been without its critics. Concerns have been raised about the potential for increased prescription abuse and the implications for public health. Opponents argue that expanding prescribing authority could lead to higher rates of addiction, particularly in a state grappling with opioid-related issues. In response, the bill includes safeguards requiring state licensing boards to demonstrate a low risk of diversion or abuse before implementing any new exemptions.

The implications of HB 389 extend beyond healthcare. Economically, it could reduce the burden on emergency services by allowing patients to manage pain more effectively at home. Socially, it aims to improve the quality of life for individuals recovering from surgery, ensuring they have access to necessary medications without unnecessary delays.

As the bill moves through the legislative process, experts are closely monitoring its progress. If passed, HB 389 could set a precedent for similar legislation in other states, potentially reshaping the landscape of pain management in the U.S. The next steps will involve further discussions and potential amendments as lawmakers weigh the benefits against the risks associated with expanded prescribing powers.